About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Our main scientific interest is to understand, from a multidisciplinary and translational approach, the molecular and cellular processes leading to renal dysfunction in several kidney pathologies. Specifically, our research lines are
We are experts on the following areas:
To sum up, our research main objective is to combine –omic data from cellular and animal models with patients’ data to identify novel biomarkers and possible treatments for several renal diseases.
IP: Concepció Jacobs Cachá Collaborators: Manuel Hernández González, Natalia Ramos Terrades, Joana Sellarés Roig, Carmen Llorens Cebriá, Mercedes López González, Janire Perurena Prieto Funding agency: Sociedad Española de Nefrología (S.E.N.) Funding: 24000 Reference: SENEFRO/PROJECTES/2023/JACOBS Duration: 23/12/2023 - 22/12/2025
IP: Fucosylation in Clear Cell Renal Cell Carcinoma. STATing novel biomarkers and therapeutic strategies Collaborators: Gerard Cantero Recasens, Miriam Izquierdo Sans Funding agency: Asociación Española Contra el Cáncer Funding: 150000 Reference: INVES234762CANT Duration: 15/11/2023 - 14/11/2026
IP: Gerard Cantero Recasens Collaborators: - Funding agency: Mizutani Foundation for Glycoscience Funding: 45000 Reference: MIZUTANI FOUNDATION FOR GLYCOSCIENCE - 2022 Duration: 01/04/2023 - 31/03/2025
IP: Patologia Cel·lular Collaborators: Gema Ariceta Iraola, Alejandro Cruz Gual, Gerard Cantero Recasens, David Lorente García, Marina Muñoz López, Mercedes López González, Hector Rios Duro, Mónica Durán Fernández, Luis Augusto Castro Sáder, Gloria Mª Fraga Rodriguez, Julieta Torchia Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 40000 Reference: 2021 SGR 01600 Duration: 01/01/2022 - 30/06/2025
Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research
The aim of the project is to establish kidney organoids derived from patients with familial hypomagnesaemia with hypercalciuria and nephrocalcinosis, which will be essential tools for studying the disease and testing new treatments.
The work identifies variants in genes such as NFU1 that, combined with the disease-causing mutation, can accelerate kidney deterioration.
